代谢综合征
医学
哮喘
血脂异常
肥胖
胰岛素抵抗
儿科
初潮
内科学
重症监护医学
作者
Jenny Garmendia,Dolores Moreno,Alexis García,Juan B. De Sanctis
出处
期刊:Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
日期:2014-02-01
卷期号:8 (1): 60-66
被引量:26
标识
DOI:10.2174/1872214807666140107151023
摘要
Metabolic syndrome (MetS) is a syndrome that involves at least three disorders dyslipidemia, insulin resistance, obesity and/or hypertension. MetS has been associated with several chronic diseases in the adulthood; however, in the recent years, the syndrome was redefined in children. Girls with early menarche and asthma, and children with MetS and asthma that reach adulthood appear to have higher risk to develop severe or difficult to control asthma and a higher probability to suffer cardiovascular diseases. It has been proposed that patients with MetS and endocrinological disorders should be considered a different entity in which pharmacologic treatment should be adjusted according to the individual. Recent patents on the field have addressed new issues on how endocrine control should be managed along with asthma therapeutics. In the near future, new approaches should decrease the high morbidity and mortality associated to these types of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI